A Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the GP100 Antigen With Immunization Using a Recombinant RF-GP100P209 Virus Encoding a GP100 Peptide Following a Nonmyeloblative Lymphocyte Depleting Regimen.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fowlpox virus vector-gp100 (Primary) ; Aldesleukin; Autolymphocyte therapy; Cyclophosphamide; Fludarabine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Jun 2012 Biomarkers information updated
- 27 Feb 2012 Actual end date changed from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Actual end date changed from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.